1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998;83:2638-48.
[CROSSREF] [PUBMED]
2. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group: an American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-17.
[CROSSREF] [PUBMED]
3. Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol 2010;21:16-24.
[CROSSREF] [PUBMED]
4. Montone KT, Baloch ZW, LiVolsi VA. The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 2008;132:1241-50.
[PUBMED]
5. Kure S, Ohashi R. Thyroid Hurthle cell carcinoma: clinical, pathological, and molecular features. Cancers (Basel) 2020;13:26.
[CROSSREF] [PUBMED] [PMC]
6. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 1989;63:908-11.
[CROSSREF] [PUBMED]
7. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013;98:E962-72.
[CROSSREF] [PUBMED] [PMC] [PDF]
8. LIoyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs; 10th ed. Lyon: International Agency for Research on Cancer; 2017.
9. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer 2013;119:504-11.
[CROSSREF] [PUBMED] [PDF]
10. Phitayakorn R, McHenry CR. Follicular and Hurthle cell carcinoma of the thyroid gland. Surg Oncol Clin N Am 2006;15:603-23.
[PUBMED]
11. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordonez NG, et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003;97:1186-94.
[CROSSREF] [PUBMED]
12. Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery 2013;154:1263-71.
[CROSSREF] [PUBMED]
13. Khafif A, Khafif RA, Attie JN. Hurthle cell carcinoma: a malignancy of low-grade potential. Head Neck 1999;21:506-11.
[CROSSREF] [PUBMED]
14. Bhattacharyya N. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg 2003;129:207-10.
[CROSSREF] [PUBMED]
15. Kim WG, Yim JH, Kim EY, Kim TY, Gong G, Yoon JH, et al. Preoperative cytological diagnosis of follicular thyroid carcinoma and Huthle cell carcinoma. J Korean Thyroid Assoc 2010;3:149-54.
16. Kim WG, Kim TY, Kim TH, Jang HW, Jo YS, Park YJ, et al. Follicular and Hurthle cell carcinoma of the thyroid in iodine-sufficient area: retrospective analysis of Korean multicenter data. Korean J Intern Med 2014;29:325-33.
[CROSSREF] [PUBMED] [PMC]
17. Kim TH, Lim JA, Ahn HY, Lee EK, Min HS, Kim KW, et al. Tumor size and age predict the risk of malignancy in Hurthle cell neoplasm of the thyroid and can therefore guide the extent of initial thyroid surgery. Thyroid 2010;20:1229-34.
[CROSSREF] [PUBMED]
18. Santana NO, Freitas RM, Marcos VN, Chammas MC, Camargo RY, Schmerling CK, et al. Diagnostic performance of thyroid ultrasound in Hurthle cell carcinomas. Arch Endocrinol Metab 2019;63:300-5.
[PUBMED]
19. Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol 2016;17:370-95.
[CROSSREF] [PUBMED] [PMC]
20. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017;27:1341-6.
[CROSSREF] [PUBMED]
21. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
22. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
[CROSSREF] [PUBMED]
23. Jin M, Kim ES, Kim BH, Kim HK, Yi HS, Jeon MJ, et al. Clinical implication of World Health Organization classification in patients with follicular thyroid carcinoma in South Korea: a multicenter cohort study. Endocrinol Metab (Seoul) 2020;35:618-27.
[CROSSREF] [PUBMED] [PMC]
24. Mills SC, Haq M, Smellie WJ, Harmer C. Hurthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol 2009;35:230-4.
[PUBMED]
25. Oluic B, Paunovic I, Loncar Z, Djukic V, Diklic A, Jovanovic M, et al. Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience. BMC Cancer 2017;17:371.
[CROSSREF] [PUBMED] [PMC]
26. Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015;100:55-62.
[CROSSREF] [PUBMED]
27. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-37.
[CROSSREF] [PUBMED]
28. Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D’Armiento M. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hurthle cell neoplasm. Thyroid 2009;19:355-60.
[CROSSREF] [PUBMED]
29. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol 2006;34:330-4.
[CROSSREF] [PUBMED]
30. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974;139:555-60.
[PUBMED]
31. Yutan E, Clark OH. Hurthle cell carcinoma. Curr Treat Options Oncol 2001;2:331-5.
[PUBMED]